Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease
Related Experiment Video
Updated: Oct 17, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
W Renner1, H Köppel, M Brodmann
1Department of Medicine, Karl Franzens University, Graz, Austria. wilfried.renner@kfunigraz.ac.at
Background:
G to A mutations at positions 20210 of the prothrombin gene (F2) and 1691 of the factor V gene (F5) are established risk factors for venous thrombosis. Several factors associated with coagulation and/or fibrinolysis have been associated with arterial occlusive disease, but the role of F2 20210A and F5 1691A for arterial occlusive disease remains unclear.
Objective:
To investigate if F2 20210A and F5 1691A are associated with peripheral arterial occlusive disease (PAOD).
Methods And Results:
We analyzed the prevalence of F2 20210A and F5 1691A alleles in 336 patients with documented PAOD at Fontaine stage II-IV and 300 controls without vascular disease. Allele frequencies in patients and controls were 0.013 and 0.022 for F2 20210A, and 0.042 and 0.045 for F5 1691, respectively, both differences being not statistically significant.
Conclusion:
Our data suggest that mutations F2 G20210A and F5 G1691A are not associated with PAOD.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants